Logistic regression analysis showed that only AHI was a predictor of daytime hypercapnia ... daytime hypercapnia may be directly linked to sleep apnea in a subgroup of patients with OSAS.

GLP-1 RAs are associated with a significant decrease in apnea-hypopnea index among patients with moderate to severe OSA and without diabetes.

Topline data were announced from a phase 3 trial evaluating AD109 (aroxybutynin 2.5mg/atomoxetine 75mg) in participants with obstructive sleep apnea.

A recent post-hoc analysis of the SURMOUNT-OSA trials revealed that tirzepatide significantly improves obstructive sleep ...

This combination is expected to improve oxygenation during sleep by increasing upper ... was the mean change from baseline in the apnea-hypopnea index (AHI) at 26 weeks as measured by polysomnography.